CytomX Therapeutics, Inc.

Develops tumor-activated antibody therapeutics for more targeted, less toxic cancer treatments.

CTMX | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 151 OYSTER POINT BLVD., 94080 SOUTH SAN FRANCISCO
Website:: https://cytomx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing a novel class of investigational antibody therapeutics. The company's core technology is its proprietary Probody® platform, which is designed to create conditionally activated biologics. These therapeutics remain masked and inactive in healthy tissue but are activated specifically within the tumor microenvironment. This approach aims to enhance the therapeutic window, enabling more potent and targeted anti-cancer treatments with potentially reduced toxicity. CytomX is advancing a deep pipeline of Probody therapeutics, both independently and through strategic collaborations, to bring new treatment options to cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CytomX Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CytomX Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for CytomX Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
ABIONYX Pharma Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.	France	ABNX
Abliva Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.	Sweden	ABLI
Abpro Holdings, Inc. Clinical-stage biotech developing antibody therapies for oncology & ophthalmology.	United States of America	ABP
AB Science Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.	France	AB
ACADIA PHARMACEUTICALS INC Develops and commercializes innovative therapies for CNS disorders and rare diseases.	United States of America	ACAD
Access Bio, Inc. Develops and manufactures rapid diagnostic tests for infectious diseases for global health.	United States of America	950130
ACHIEVE LIFE SCIENCES, INC. Developing cytisinicline, a plant-based treatment for smoking cessation and nicotine addiction.	United States of America	ACHV
AC Immune SA Developing precision medicine to diagnose, treat, and prevent neurodegenerative diseases.	United States of America	ACIU
Aclaris Therapeutics, Inc. A clinical-stage biopharma developing novel drugs for immuno-inflammatory diseases.	United States of America	ACRS
Actinium Pharmaceuticals, Inc. Develops targeted radiotherapies for advanced cancers like AML and prostate cancer.	United States of America	ATNM